Key facts
- This page summarizes Janus Henderson Group Ltd.'s Form 4 filing for ARCA biopharma, Inc. (ORKA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 20 Aug 2024, 14:23.
Janus Henderson Group Ltd. - 16 Aug 2024 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- ORKA
- Reported as of
- 16 Aug 2024
- Net transaction value
- +$17,067
- SEC form
- 4
- Accepted by SEC
- 20 Aug 2024, 14:23:17 UTC
- Prior SEC filing
- 26 Jul 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michelle Rosenberg, CAO, General Counsel & Company Secretary
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Janus Henderson Group Ltd. filed Form 4 for ARCA biopharma, Inc. (ORKA) on 20 Aug 2024.
Change
- Previous filing in this sequence was filed on 26 Jul 2024.
- Current net transaction value: +$17,067.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABIO
transaction
Common Stock
Purchase
- Transaction value
- $15,793
- Shares
- +5,390
- Change %
- +0.26%
- Price
- $2.93
- Shares after
- 2,116,785
- Date
- 16 Aug 2024
- Ownership
- By Fund
- Footnotes
- F1
ABIO
transaction
Common Stock
Purchase
- Transaction value
- $1,274
- Shares
- +428
- Change %
- +0.02%
- Price
- $2.98
- Shares after
- 2,117,213
- Date
- 16 Aug 2024
- Ownership
- By Fund
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.